期刊文献+

微小RNA活性分析法筛选前列腺癌去势抵抗转化相关微小RNA的实验研究 被引量:6

Screening key micro RNAs for castration-resistant prostate cancer based on micro RNA activity analysis method
原文传递
导出
摘要 目的探讨微小RNA(miRNA)活性分析法筛选前列腺癌去势抵抗转化相关miRNA的效率。方法应用miRNA活性分析法筛选出在前列腺癌去势抵抗过程中潜在的发挥活性作用的miRNAs。培养人激素敏感型前列腺癌LNCAP细胞(对照组)及人去势抵抗型前列腺癌C4-2细胞(C4-2组)、PC-3细胞(PC-3组)、DU-145细胞(DU-145组),提取各组细胞总RNA,采用实时荧光定量PCR(qPCR)检测miRNAs,比较各组细胞miRNAs的表达情况。结果应用miRNA活性分析法,依据筛选流程,共选出9个差异表达的miRNAs,分别为miR-1、miR-122、miR-218、miR-145、miR-155、miR-210、miR-197、miR-346、let-7b。采用qPCR检测这9个miRNAs,结果显示,7个miRNAs在两种不同状态下的前列腺癌细胞中存在差异表达;在不同去势抵抗型前列腺癌细胞中,miR-210、miR-197、miR-346、miR-218均明显高表达,而miR-122、miR-145、let-7b均明显低表达。结论采用miRNA活性分析法筛选前列腺癌去势抵抗转化相关miRNA,有着较高的准确性与可信度;其具体转化过程还需进一步证实。 Objective To explore the efficiency of micro RNA(miRNA) activity analysis method in screening the miRNA associated with castration resistance in prostate cancer. Methods miRNAs were screened for their potential role in castration resistance of prostate cancer by miRNAs activity analysis method. Human hormone-sensitive prostate cancer LNCAP cells (control group) and castration-resistant prostate cancer C4-2 cells (C4-2 group), PC-3 cells (PC-3 group) and DU-145 cells (DU-145 group) were cultured. Total RNA was extracted from each group. Real-time fluorescence quantitative PCR (qPCR) was used to detect miRNAs and compare the expression of miRNAs in each group. Results According to the screening process, 9 differentially expressed miRNAs were identified by miRNA activity analysis method. They were miR-1, miR-122, miR-218, miR-145, miR-155, miR-210, miR-197, miR-346 and let-7b. The 9 miRNAs were detected by qPCR. The results showed that 7 miRNAs were differentially expressed in prostate cancer cells in two different states. In different castration-resistant prostate cancer cells, miR-210, miR-197, miR-346 and miR-218 were significantly over expressed, while miR-122, miR-145 and let-7b were significantly under expressed. Conclusions The screening of castration-resistant transformation-related miRNAs in prostate cancer by miRNAs activity analysis method has high accuracy and reliability, and the specific transformation process needs further confirmation.
作者 王苏贵 吴自余 李强 李乾 王磊 张文宇 阳东荣 姜福金 Wang Sugui;Wu Ziyu;Li Qiang;Li Qian;Wang Lei;Zhang Wenyu;Yang Dongrong;Jiang Fujin(Department of Urology, Huai'an Hospital Affiliated of Xuzhou Medical University , Huai'an 223002, China)
出处 《中华解剖与临床杂志》 2018年第6期538-542,共5页 Chinese Journal of Anatomy and Clinics
基金 国家自然科学基金 (81472776) 淮安市自然科学基金 (HAB201730) 徐州医科大学附属淮安医院科研基金 (YK201506).
关键词 前列腺癌 系统生物学 微小RNA Prostate cancer Systemic biology Micro RNA
  • 相关文献

参考文献8

二级参考文献54

  • 1Schnadig ID, Beer TM. Optimal timing of chemotherapy in andro- gen independent prostate cancer[ J]. Urol Oncol,2009,27 (1) :97 -100.
  • 2Martindale. The Extra Pharmacopoeia 31ed London: The Royal Pharmaceutical Society, 1996. 545.
  • 3Small E J, Halabis, Dawsonna, et al. Anti - androgen withdrawal a- lone or in combination with ketoconazole in androgen - independ- ent prostate cancer patients:a phase Ⅲ trial( CALGB 8583 ) [ J ]. J Clin Onco1,2004,22 (6) : 1025 - 1033.
  • 4De Bono JS, Logothetis C J, Molina A, et al. Abiraterone and in- creased Survival in metastatic prostate cancer[ J ]. N Engl J Med, 2011,364 (21) : 1995 - 2005.
  • 5Rawlinson A, Mohammed A, Beatty J, et al. The role of abiraterone in the management of metastatic castration - resistant prostate cancer[ J ]. Expert Rev Anticancer Ther,2012,12 (4) :429 - 437.
  • 6Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalu- tamide in prostate cancer after chemotherapy [ J]. N Engl J Med, 2012,367(13) :1187 - 1197.
  • 7Galsky MD, Dritselis A, Kirkpatrick P, et al. Nat Rev Drug Dis- coy 2010;9(9) :677 -678.
  • 8Nakagami Y, Ohori M, Sakamoto N, et al. Safety and efficacy of docetaxel,estramustine phosphate and hydrocortisone in hormone - refractory prostate cancer patients [ J]. Int J Uml, 2010, 177 (7) :629 -634.
  • 9Kuramoto T, Inagaki T, Fujii R, et al. Docetaxel in combination with estramustine and prednisolone for castration - resistant pros- tate cancer[J]. Int J Clin Oncol,2012. E pub ahead of orint.
  • 10Fernandez O, Afonso J, Vazquez S, et al. Metastatic castration - resistant prostate cancer: changing landscape with cabazitaxel [ J ]. Anticancer Drugs,2014,25 ( 3 ) :237 - 243.

共引文献24

同被引文献42

引证文献6

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部